

ELA-32(human) TFA

Cat. No.:	HY-P2196A	
Molecular Formula:	C ₁₇₂ H ₂₉₀ F ₃ N ₆₃ O ₄₁ S ₄	
Molecular Weight:	4081.84	
Sequence Shortening:	QRPVNLTMRRLRKHNLQRRRCMPLHSRVPPF (Disulfide bridge: Cys17-Cys22)	QRPVNLTMRRLRKHNLQRRRCMPLHSRVPPF (Disulfide bridge: Cys17-Cys22) (TFA salt)
Target:	Apelin Receptor (APJ)	
Pathway:	GPCR/G Protein	
Storage:	Sealed storage, away from moisture and light, under nitrogen	
	Powder	-80°C 2 years -20°C 1 year
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)	

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 100 mg/mL (24.50 mM; Need ultrasonic)					
		Solvent Concentration	Mass			
	Preparing Stock Solutions			1 mg	5 mg	10 mg
		1 mM		0.2450 mL	1.2249 mL	2.4499 mL
		5 mM		0.0490 mL	0.2450 mL	0.4900 mL
	10 mM		0.0245 mL	0.1225 mL	0.2450 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: PBS Solubility: 100 mg/mL (24.50 mM); Clear solution; Need ultrasonic					

BIOLOGICAL ACTIVITY

Description	ELA-32(human) TFA is a potent, high affinity apelin receptor agonist (IC ₅₀ =0.27 nM; K _d =0.51 nM). ELA-32(human) TFA exhibits no binding GPR15 and GPR25. ELA-32(human) TFA activates the PI3K/AKT pathway and promotes self-renewal of hESCs via cell-cycle progression and protein translation. ELA-32(human) TFA also potentiates the TGFβ pathway, priming hESCs toward the endoderm lineage. ELA-32(human) TFA stimulates angiogenesis in HUVEC cells.
--------------------	---

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA